Results 201 to 210 of about 184,433 (313)

Effects of interferon-[alpha], verapamil and dacarbazine in the treatment of advanced malignant melanoma

, 2003
Treatment of patients with metastatic melanoma with either dacarbazine (DTIC) or interferon-[alpha] (IFN[alpha]) as single drugs, or in combination, results in a response rate of approximately 15–20%.
Hofer, Åke,, Henriksson, Roger,, Riklund-Åhlström, Katrine,, Andersson, Ronny,   +3 more
core  

​The Reconstruction of a Massive Occipital Defect With a Bilateral Temporal Advancement Flap Following Advanced Melanoma Resection: A Case Report. [PDF]

Cureus
Rodríguez Enríqeuz JD, Córdova López E, Bautista Badal MA, Palacios Zaragoza PA, Bernal González AD.   +4 more
europepmc   +1 more source

A Mouse Model of Depression‐Tumor Multimorbidity Reveals the Mechanism of Tumor Growth Accelerated by Depression

Animal Research and One Health, EarlyView.
Depression accelerates tumor growth by dysregulation of tumor immune microenvironment. (A) Modeling methods: Subcutaneous tumor models were established under chronic unpredictable mild stress conditions, including cold swimming, physical restraint, and food/water deprivation, leading to increased tumor growth.
Yakun Ren, Xinpei Wang, Wen Wang, Xingjiu Yang, Mengyuan Li, Jing Du, Ran Gao   +6 more
wiley   +1 more source

Neoadjuvant Therapy in Resectable Advanced Melanoma: Swiss Real-World Data. [PDF]

Cancers (Basel)
Blumenröther AK, Fang Y, El Saadany T, Ramelyte E, Hasan Ali O, Kündig T, Mihic-Probst D, Steiner S, Maurer A, Dummer R, Mangana J, Maul LV.   +11 more
europepmc   +1 more source

A Multifaceted Interplay Among Hemophagocytosis, Interleukin‐18, and Type I Interferon Distinguishes Still Disease From Other Autoinflammatory Diseases

Arthritis &Rheumatology, EarlyView.
Objective The unknown pathophysiology and the lack of specific features for systemic juvenile idiopathic arthritis and adult‐onset Still disease (collectively known as Still disease; SD) delay diagnosis and appropriate treatment. The goal of this study was to identify features and mechanisms that distinguish SD from other systemic autoinflammatory ...
Yvonne M. Mueller, Charlotte Girard, Harmen J. G. van de Werken, Stefan J. Erkeland, Dwin G. B. Grashof, Laurie Vaillant, Renske J. H. den Dekker, Iris van Zuijen, Sharon Veenbergen, Fanny Coffin, Eric Bindels, Yvan Jamilloux, Katerina Laskari, Vassili Soumelis, Bruno Fautrel, Cem Gabay, Peter D. Katsikis   +16 more
wiley   +1 more source

Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma. [PDF]

J Immunother Cancer
Yamada MM, Chandrasekhar S, Gooley TA, Chen RE, Doolittle-Amieva C, Ansstas G, Bhatia S, Hall ET, Nghiem PT, Park SY, Chen DY.   +10 more
europepmc   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Clinical Effectiveness and Safety of Electrochemotherapy (ECT) in the Treatment of Locally Advanced Melanoma: A Systematic Review. [PDF]

Cureus
Vickars DJ, Mandal A.
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source